Sunjay Shah, MD
Radiation Oncology · Newark, DENPI 1538103551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,500 of the $6,616 with a category attached, or 68.0%. Novocure Inc. accounts for 83.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $5,173 and has fallen 85.5% since, to $752 in 2025.
Across 27 payments — averaging $245.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$6K
- Zap Surgical Systems, Inc.$507
- Siemens Medical Solutions USA, Inc.$284
- Viewray Technologies Inc$153
- Lilly USA, LLC$92
- Elekta, Inc.$29
What the payments were for
- Speaking & faculty fees$4,50068%
- Travel & lodging$4737%
- Food & beverage$1,45522%
- Entertainment$1893%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 14 | $5,552 |
| Zap Surgical Systems, Inc. | 8 | $507 |
| Siemens Medical Solutions USA, Inc. | 2 | $284 |
| Viewray Technologies Inc | 1 | $153 |
| Lilly USA, LLC | 1 | $92 |
| Elekta, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few radiation oncology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 99 | $1,771 |
| Sucralfate | 12 | $1,383 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Newark
- Jon StrasserNewark$365K
- Adam RabenNewark$84K
- Gaurav ShuklaNewark$3K
- Lindsay RomakNewark$3K
- Lana de Souza LawrenceNewark$333
- Christopher KoprowskiNewark$20
- Andrejs StraussRehoboth Beach$2K
- Owen ThomasRehoboth Beach$1K
- Jennifer HungRehoboth Beach$715
- Tony LeeDover$567
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.